Megalotect

Human Cytomegalovirus Immunoglobulin, the active ingredient in Megalotect, is an immunoglobulin presented as a sterile liquid preparation for intravenous use. It provides passive immunity by supplying antibodies that neutralize human cytomegalovirus in patients at risk of severe infection. GNH USA supplies Megalotect as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Megalotect is used in the management of cytomegalovirus (CMV) disease and its prevention in immunocompromised patients. - Solid organ transplant recipients: reduces the incidence of CMV disease after transplantation. - Hematopoietic stem cell transplant recipients: provides prophylaxis against CMV reactivation. - Patients with primary CMV infection: aids in viral clearance when conventional antivirals are insufficient.

Megalotect may be associated with infusion‑related and immunologic reactions.

Common Side Effects: - Fever: transient rise in body temperature during or after infusion. - Chills: shaking sensations commonly reported with intravenous immunoglobulins. - Headache: mild to moderate headache occurring shortly after administration. - Nausea: occasional upset stomach or feeling of queasiness. - Rash: mild erythematous skin eruption at the infusion site. - Mild hypertension: temporary increase in blood pressure during infusion.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical intervention. - Renal dysfunction: acute kidney injury, especially in patients with pre‑existing renal disease. - Thromboembolic events: clot formation leading to deep‑vein thrombosis or pulmonary embolism. - Hemolysis: destruction of red blood cells causing anemia. - Severe hypotension: marked drop in blood pressure during infusion. - Aseptic meningitis: rare inflammatory response of the meninges without infection.

Megalotect should be administered with careful monitoring of patient status and laboratory parameters. - Renal impairment: monitor serum creatinine and adjust infusion rate as needed. - Thromboembolic risk: assess history of clotting disorders before use. - Known hypersensitivity to blood products: avoid administration in allergic individuals. - Pregnancy: consider only if potential benefit outweighs potential risk to the fetus. - Immunocompromised patients: observe closely for secondary infections. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Megalotect may interact with other agents that affect immune function or blood viscosity.

Major Interactions (Avoid): - Live vaccines: concurrent use may result in uncontrolled infection. - Other CMV hyperimmune globulins: duplication can increase risk of hyperviscosity. - High‑dose immunoglobulin therapy: may exacerbate renal and thrombotic complications.

Moderate Interactions (Monitor Closely): - Anticoagulants: potential enhancement of bleeding tendency. - Nephrotoxic drugs: increased risk of renal injury; monitor renal function. - Corticosteroids: may alter immunologic response to the product.